(Bloomberg) -- The jury mulling the fate of Retrophin Inc. co-founder Martin Shkreli ended the third day of deliberations without a peep.
On Tuesday, the panel had asked for the definitions of "assets under management" and "fraudulent intent," but it didn't communicate with the court on Wednesday.
The 34-year-old Shkreli, known as "Pharma Bro," is accused of taking money from investors in his previous hedge funds and using it to start Retrophin, then using the drug-development company's cash to pay them back. He faces as long as 20 years in prison if convicted of the most serious charges against him.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
The case is U.S. v. Shkreli, 15-cr-0637, U.S. District Court, Eastern District of New York (Brooklyn).
To contact the reporter on this story: Chris Dolmetsch in New York State Supreme Court in Manhattan at cdolmetsch@bloomberg.net.
To contact the editors responsible for this story: David Glovin at dglovin@bloomberg.net, Joe Schneider, Paul Cox
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
